Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $17.76, for a total value of $1,156,051.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.10, for a total value of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.25, for a total value of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.75, for a total value of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.76, for a total value of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The stock was sold at an average price of $19.02, for a total value of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.44, for a total value of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.67, for a total value of $265,050.00.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.28, for a total transaction of $172,800.00.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The stock was sold at an average price of $18.06, for a total transaction of $304,762.50.

Crispr Therapeutics AG (CRSP) traded up $0.01 during trading on Thursday, hitting $18.53. 197,500 shares of the stock traded hands, compared to its average volume of 142,711. Crispr Therapeutics AG has a 1 year low of $11.63 and a 1 year high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company had revenue of $2.39 million for the quarter, compared to the consensus estimate of $3.61 million. During the same period in the prior year, the firm posted ($2.77) EPS. The business’s revenue was up 54.2% on a year-over-year basis. sell-side analysts expect that Crispr Therapeutics AG will post -2.46 EPS for the current fiscal year.

Several brokerages have issued reports on CRSP. SunTrust Banks reissued a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a research note on Friday, November 10th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Barclays reissued a “buy” rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a research note on Friday, September 8th. BidaskClub downgraded shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Finally, Chardan Capital reissued a “buy” rating on shares of Crispr Therapeutics in a research note on Monday, August 14th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $22.38.

Institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN raised its stake in shares of Crispr Therapeutics by 459.7% during the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after acquiring an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC bought a new stake in shares of Crispr Therapeutics during the third quarter valued at approximately $193,000. Ark Investment Management LLC bought a new stake in shares of Crispr Therapeutics during the second quarter valued at approximately $206,000. Moloney Securities Asset Management LLC bought a new position in Crispr Therapeutics in the third quarter worth approximately $235,000. Finally, Bank of New York Mellon Corp bought a new position in Crispr Therapeutics in the third quarter worth approximately $288,000. 24.55% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/07/crispr-therapeutics-ag-crsp-major-shareholder-corp-de-celgene-sells-65093-shares.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.